Home
/ Rushi
/ Competitors

Rushi Competitors and Similar CompaniesClear all

Rushi's competitors and similar companies include Medisca, Industria Farmaceutica Galenica Senese, Daewoong Pharmaceutical and Abiomed.

	Rushi Rushi is a pharmaceutical company.	Medisca Medisca is an FDA-registered supplier of quality pharmacy compounding products and services.	Industria Farmaceutica Galenica Senese Industria Farmaceutica Galenica Senese is a company that manufactures and develops medical products for infusion and injection.	Daewoong Pharmaceutical Daewoong Pharmaceutical (대웅제약) is a company that provides pharmaceutical solutions and services.	Abiomed Abiomed is a company providing medical devices for circulatory support.
Founding Date	Founding Date 1990	Founding Date 1989	Founding Date 1949	Founding Date 2002	Founding Date 1981
Type	Type Private	Type Private	Type Private	Type Public	Type Subsidiary
Tags	Tags Healthcare chemicals medical devices pharma	Tags Healthcare chemicals medical devices pharma	Tags Healthcare clinical research medical devices	Tags Healthcare drug development medical devices pharma	Tags Healthcare medical devices pharma
Locations	Locations Mumbai, IN HQ	Locations Montréal, CA HQ Sydney, AU Richmond, CA Irving, US Las Vegas, US Plattsburgh, US	Locations Monteroni d'Arbia, IT HQ	Locations Seoul, KR HQ Hyderabad, IN Taguig City, PH Bangkok, TH	Locations Danvers, US HQ Aachen, DE Tokyo, JP Halethorpe, US
Employees	Employees 23	Employees 3871% increase	Employees 1471% decrease	Employees 1,669	Employees 2,00316% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₩2.1t (FY, 2025)	Revenue (est.) $1b (FY, 2022)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods (₩2b) (FY, 2025)	Cost of goods $188.2m (FY, 2022)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ₩2.1t (FY, 2025)	Gross profit $843.6m (FY, 2022)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income ₩227.9b (FY, 2025)	Net income $136.5m (FY, 2022)